Login Register Cart 0
Endocrine, Metabolic & Immune Disorders - Drug Targets

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

ICPi-Induced Graves' Disease with Pre-existing Autoimmune Thyroid Disorders: A Case Report and Literature Review

Author(s): Xinpan Wang, Doudou Chen, Yun Shi, Tao Yang and Xuqin Zheng*

Volume 26, 2026

Published on: 10 February, 2025

Article ID: e18715303317264

Pages: 8

DOI: 10.2174/0118715303317264250116095028

open_access

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

Background: Immune Checkpoint Inhibitor (ICPi) therapy has revolutionized cancer treatment but can lead to immune-related adverse events (irAE), including thyroid dysfunction. The impact of ICPi on patients with pre-existing autoimmune thyroid diseases (PATD), particularly the development of Graves' disease, remains poorly understood.

Case Presentation: We provide the first complete case of Graves' disease with ICPi therapy in a patient who already had Hashimoto's thyroiditis. The patient, a 52-year-old male, was diagnosed with lung adenocarcinoma and received Atezolizumab. Clinical evaluation revealed hyperthyroidism, confirmed by elevated thyroid hormones and autoantibodies (TRAb and TSAb). The patient was managed with methimazole and demonstrated a transient hyperthyroid phase followed by persistent hypothyroidism. Only 16 confirmed cases of Graves' disease induced by ICPi were reported. We conducted a review to investigate the clinical characteristics, risk factors, and prognosis trends associated with ICPi-induced Graves disease in PTAD patients. Additionally, changes in thyroid function and autoantibodies during and after ICPi treatment are examined.

Conclusion: This case underscores the importance of monitoring thyroid function and autoantibodies in patients with PATD undergoing ICPi therapy. The findings suggest distinct differences in the humoral immune response between ICPi-induced and spontaneous Graves' disease, necessitating further research into autoantibody dynamics and their relationship with cellular immunity in these patients.

Keywords: Immune checkpoint inhibitor, Graves' disease, thyroid toxicity, autoimmune disease, autoantibody, hyperthyroidism.

[1]
Wright, J.J.; Powers, A.C.; Johnson, D.B. Endocrine toxicities of immune checkpoint inhibitors. Nat. Rev. Endocrinol., 2021, 17(7), 389-399.
[http://dx.doi.org/10.1038/s41574-021-00484-3] [PMID: 33875857]
[2]
Chiloiro, S.; Bianchi, A.; Giampietro, A.; Milardi, D.; De Marinis, L.; Pontecorvi, A. The changing clinical spectrum of endocrine adverse events in cancer immunotherapy. Trends Endocrinol. Metab., 2022, 33(2), 87-104.
[http://dx.doi.org/10.1016/j.tem.2021.10.009] [PMID: 34895977]
[3]
Ramos-Casals, M.; Sisó-Almirall, A. Immune-related adverse events of immune checkpoint inhibitors. Ann. Intern. Med., 2024, 177(2), ITC17-ITC32.
[http://dx.doi.org/10.7326/AITC202402200] [PMID: 38346306]
[4]
Wang, S.J.; Dougan, S.K.; Dougan, M. Immune mechanisms of toxicity from checkpoint inhibitors. Trends Cancer, 2023, 9(7), 543-553.
[http://dx.doi.org/10.1016/j.trecan.2023.04.002] [PMID: 37117135]
[5]
Tison, A.; Garaud, S.; Chiche, L.; Cornec, D.; Kostine, M. Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases. Nat. Rev. Rheumatol., 2022, 18(11), 641-656.
[http://dx.doi.org/10.1038/s41584-022-00841-0] [PMID: 36198831]
[6]
Sparks, J.A. Pre-existing autoimmune diseases and immune checkpoint inhibitors for cancer treatment: Considerations about initiation, flares, immune-related adverse events, and cancer progression. Rheum. Dis. Clin. North Am., 2024, 50(2), 147-159.
[http://dx.doi.org/10.1016/j.rdc.2024.01.001] [PMID: 38670718]
[7]
Sumimoto, H.; Noda, S.; Koide, H.; Douke, Y.; Sakai, K.; Nishikawa, A.; Tomioka, A.; Hori, M.; Nakato, H.; Kimura, Y.; Tokuda, A.; Takano, A.; Teramoto, K.; Murata, S.; Daigo, Y. Pre-existing autoimmune disease as a risk factor for immune-related adverse events in cancer patients receiving immune checkpoint inhibitors. PLoS One, 2024, 19(7), e0306995.
[http://dx.doi.org/10.1371/journal.pone.0306995] [PMID: 39012903]
[8]
Kehl, K.L.; Yang, S.; Awad, M.M.; Palmer, N.; Kohane, I.S.; Schrag, D. Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. Cancer Immunol. Immunother., 2019, 68(6), 917-926.
[http://dx.doi.org/10.1007/s00262-019-02321-z] [PMID: 30877325]
[9]
Zhang, K.; Kong, X.; Li, Y.; Wang, Z.; Zhang, L.; Xuan, L. PD-1/PD-L1 inhibitors in patients with preexisting autoimmune diseases. Front. Pharmacol., 2022, 13, 854967.
[http://dx.doi.org/10.3389/fphar.2022.854967] [PMID: 35370736]
[10]
Iwama, S.; Kobayashi, T.; Yasuda, Y.; Arima, H. Immune checkpoint inhibitor-related thyroid dysfunction. Best Pract. Res. Clin. Endocrinol. Metab., 2022, 36(3), 101660.
[http://dx.doi.org/10.1016/j.beem.2022.101660] [PMID: 35501263]
[11]
Lu, D.; Yao, J.; Yuan, G.; Gao, Y.; Zhang, J.; Guo, X. Immune checkpoint inhibitor-related new-onset thyroid dysfunction: A retrospective analysis using the US FDA adverse event reporting system. Oncologist, 2022, 27(2), e126-e132.
[http://dx.doi.org/10.1093/oncolo/oyab043] [PMID: 35641200]
[12]
Wiersinga, W.M.; Poppe, K.G.; Effraimidis, G. Hyperthyroidism: Aetiology, pathogenesis, diagnosis, management, complications, and prognosis. Lancet Diabetes Endocrinol., 2023, 11(4), 282-298.
[http://dx.doi.org/10.1016/S2213-8587(23)00005-0] [PMID: 36848916]
[13]
Petranović Ovčariček, P.; Görges, R.; Giovanella, L. Autoimmune thyroid diseases. Semin. Nucl. Med., 2024, 54(2), 219-236.
[http://dx.doi.org/10.1053/j.semnuclmed.2023.11.002] [PMID: 38044176]
[14]
Grixti, L.; Lane, L.C.; Pearce, S.H. The genetics of Graves’ disease. Rev. Endocr. Metab. Disord., 2024, 25(1), 203-214.
[http://dx.doi.org/10.1007/s11154-023-09848-8] [PMID: 38108994]
[15]
Pitoia, F.; Trimboli, P. New insights in thyroid diagnosis and treatment. Rev. Endocr. Metab. Disord., 2024, 25(1), 1-3.
[http://dx.doi.org/10.1007/s11154-023-09859-5] [PMID: 38041785]
[16]
Lee, S.Y.; Pearce, E.N. Hyperthyroidism. JAMA, 2023, 330(15), 1472-1483.
[http://dx.doi.org/10.1001/jama.2023.19052] [PMID: 37847271]
[17]
Lanzolla, G.; Marinò, M.; Menconi, F. Graves disease: Latest understanding of pathogenesis and treatment options. Nat. Rev. Endocrinol., 2024, 20(11), 647-660.
[http://dx.doi.org/10.1038/s41574-024-01016-5] [PMID: 39039206]
[18]
Azmat, U.; Liebner, D.; Joehlin-Price, A.; Agrawal, A.; Nabhan, F. Treatment of ipilimumab induced Graves’ disease in a patient with metastatic melanoma. Case Rep. Endocrinol., 2016, 2016, 1-4.
[http://dx.doi.org/10.1155/2016/2087525] [PMID: 26881150]
[19]
de Filette, J.; Jansen, Y.; Schreuer, M.; Everaert, H.; Velkeniers, B.; Neyns, B.; Bravenboer, B. Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J. Clin. Endocrinol. Metab., 2016, 101(11), 4431-4439.
[http://dx.doi.org/10.1210/jc.2016-2300] [PMID: 27571185]
[20]
Gan, E.H.; Mitchell, A.L.; Plummer, R.; Pearce, S.; Perros, P. Tremelimumab-induced graves hyperthyroidism. Eur. Thyroid J., 2017, 6(3), 167-170.
[http://dx.doi.org/10.1159/000464285] [PMID: 28785544]
[21]
Narayen, G.; Lieb, D. Pembrolizumab-related graves' disease: A rare adverse effect of an anti-PD-1 antibody cancer immunotherapy. J. Endocr. Soc., 2019, 3(Suppl 1), SAT-584.
[http://dx.doi.org/10.1210/js.2019-SAT-584]
[22]
Brancatella, A.; Viola, N.; Brogioni, S.; Montanelli, L.; Sardella, C.; Vitti, P.; Marcocci, C.; Lupi, I.; Latrofa, F. Graves’ disease induced by immune checkpoint inhibitors: A case report and review of the literature. Eur. Thyroid J., 2019, 8(4), 192-195.
[http://dx.doi.org/10.1159/000501824] [PMID: 31602361]
[23]
Yajima, K.; Akise, Y. A case report of Graves’ disease induced by the anti-human programmed cell death-1 monoclonal antibody pembrolizumab in a bladder cancer patient. Case Rep. Endocrinol., 2019, 2019, 1-5.
[http://dx.doi.org/10.1155/2019/2314032] [PMID: 31772785]
[24]
Iadarola, C.; Croce, L.; Quaquarini, E.; Teragni, C.; Pinto, S.; Bernardo, A.; Fonte, R.; Marinò, M.; Rotondi, M.; Chiovato, L. Nivolumab induced thyroid dysfunction: Unusual clinical presentation and challenging diagnosis. Front. Endocrinol., 2019, 9, 813.
[http://dx.doi.org/10.3389/fendo.2018.00813] [PMID: 30705667]
[25]
Yamada, H.; Okajima, F.; Onda, T.; Fujimori, S.; Emoto, N.; Sugihara, H. New-onset graves’ disease after the initiation of nivolumab therapy for gastric cancer: A case report. BMC Endocr. Disord., 2020, 20(1), 132.
[http://dx.doi.org/10.1186/s12902-020-00613-5] [PMID: 32847555]
[26]
Kurihara, S.; Oikawa, Y.; Nakajima, R.; Satomura, A.; Tanaka, R.; Kagamu, H.; Shimada, A. Simultaneous development of Graves’ disease and type 1 diabetes during anti-programmed cell death-1 therapy: A case report. J. Diabetes Investig., 2020, 11(4), 1006-1009.
[http://dx.doi.org/10.1111/jdi.13212] [PMID: 31926048]
[27]
Peiffert, M.; Cugnet-Anceau, C.; Dalle, S.; Chikh, K.; Assaad, S.; Disse, E.; Raverot, G.; Borson-Chazot, F.; Abeillon-du Payrat, J. Graves’ disease during immune checkpoint inhibitor therapy (a case series and literature review). Cancers, 2021, 13(8), 1944.
[http://dx.doi.org/10.3390/cancers13081944] [PMID: 33920721]
[28]
Reddy, C.; Zena, M. Title: Case of hyperthyroidism in a patient on Anti-PD-1 (programmed cell death receptor-1 blocking antibody) therapy caused by destructive thyroiditis followed by Graves’ disease. J. Endocr. Soc., 2021, 5(Suppl. 1), A968-A969.
[http://dx.doi.org/10.1210/jendso/bvab048.1979]
[29]
Alqaisi, S.; Rahman, A. A rare case of pembrolizumab-associated Graves’ disease. Cureus, 2023, 15(2), e34696.
[http://dx.doi.org/10.7759/cureus.34696] [PMID: 36909047]
[30]
Muir, C.A.; Wood, C.C.G.; Clifton-Bligh, R.J.; Long, G.V.; Scolyer, R.A.; Carlino, M.S.; Menzies, A.M.; Tsang, V.H.M. Association of antithyroid antibodies in checkpoint inhibitor–associated thyroid immune–related adverse events. J. Clin. Endocrinol. Metab., 2022, 107(5), e1843-e1849.
[http://dx.doi.org/10.1210/clinem/dgac059] [PMID: 35104870]
[31]
Chieng, J.H.L.; Htet, Z.W.; Zhao, J.J.; Tai, E.S.; Tay, S.H.; Huang, Y.; Wong, A.; Yang, S.P. Clinical presentation of immune-related endocrine adverse events during immune checkpoint inhibitor treatment. Cancers , 2022, 14(11), 2687.
[http://dx.doi.org/10.3390/cancers14112687] [PMID: 35681667]
[32]
Kimbara, S.; Fujiwara, Y.; Iwama, S.; Ohashi, K.; Kuchiba, A.; Arima, H.; Yamazaki, N.; Kitano, S.; Yamamoto, N.; Ohe, Y. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. Cancer Sci., 2018, 109(11), 3583-3590.
[http://dx.doi.org/10.1111/cas.13800] [PMID: 30230649]
[33]
Wang, Q.; Wu, T.; Zhao, R.; Li, Y.; Chen, X.; Shen, S.; Zhang, X. Development and validation of a prediction model for thyroid dysfunction in patients during immunotherapy. Endocr Pract, 2024, 30(10), 943-950.
[34]
Zhou, X.; Iwama, S.; Kobayashi, T.; Ando, M.; Arima, H. Risk of thyroid dysfunction in PD-1 blockade is stratified by the pattern of TgAb and TPOAb positivity at baseline. J. Clin. Endocrinol. Metab., 2023, 108(10), e1056-e1062.
[http://dx.doi.org/10.1210/clinem/dgad231] [PMID: 37084392]
[35]
Mariani, G.; Tonacchera, M.; Grosso, M.; Orsolini, F.; Vitti, P.; Strauss, H.W. The role of nuclear medicine in the clinical management of benign thyroid disorders, Part 1: Hyperthyroidism. J. Nucl. Med., 2021, 62(3), 304-312.
[http://dx.doi.org/10.2967/jnumed.120.243170] [PMID: 33008929]
[36]
Tywanek, E.; Michalak, A.; Świrska, J.; Zwolak, A. Autoimmunity, new potential biomarkers and the thyroid gland—The perspective of Hashimoto’s thyroiditis and its treatment. Int. J. Mol. Sci., 2024, 25(9), 4703.
[http://dx.doi.org/10.3390/ijms25094703] [PMID: 38731922]
[37]
Krieger, C.C.; Kahaly, G.J.; Azam, A.; Klubo-Gwiezdzinska, J.; Neumann, S.; Gershengorn, M.C. Graves’ autoantibodies exhibit different stimulating activities in cultures of thyrocytes and orbital fibroblasts not reflected by clinical assays. Thyroid, 2022, 32(1), 90-96.
[PMID: 34714162]
[38]
Stan, M.N.; Algeciras-Schimnich, A.; Murthy, V.; Thapa, P.; Araki, N. Diagnostic utility of a new assay for thyroid stimulating immunoglobulins in Graves’ disease and thyroid eye disease. Thyroid, 2022, 32(2), 170-176.
[http://dx.doi.org/10.1089/thy.2021.0299] [PMID: 34714163]
[39]
Kahaly, G.J.; Diana, T.; Kanitz, M.; Frommer, L.; Olivo, P.D. Prospective trial of functional thyrotropin receptor antibodies in Graves disease. J. Clin. Endocrinol. Metab., 2020, 105(4), e1006-e1014.
[http://dx.doi.org/10.1210/clinem/dgz292] [PMID: 31865369]
[40]
Napolitano, G.; Bucci, I.; Di Dalmazi, G.; Giuliani, C. Non-conventional clinical uses of TSH receptor antibodies: The case of chronic autoimmune thyroiditis. Front. Endocrinol., 2021, 12, 769084.
[http://dx.doi.org/10.3389/fendo.2021.769084] [PMID: 34803929]
[41]
Nalla, P.; Young, S.; Sanders, J.; Carter, J.; Adlan, M.A.; Kabelis, K.; Chen, S.; Furmaniak, J.; Rees Smith, B.; Premawardhana, L.D.K.E. Thyrotrophin receptor antibody concentration and activity, several years after treatment for Graves’ disease. Clin. Endocrinol., 2019, 90(2), 369-374.
[http://dx.doi.org/10.1111/cen.13908] [PMID: 30485487]
[42]
Bukhari, S.; Henick, B.S.; Winchester, R.J.; Lerrer, S.; Adam, K.; Gartshteyn, Y.; Maniar, R.; Lin, Z.; Khodadadi-Jamayran, A.; Tsirigos, A.; Salvatore, M.M.; Lagos, G.G.; Reiner, S.L.; Dallos, M.C.; Mathew, M.; Rizvi, N.A.; Mor, A. Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors. Cell Rep. Med., 2023, 4(1), 100868.
[http://dx.doi.org/10.1016/j.xcrm.2022.100868] [PMID: 36513074]
[43]
Yasuda, Y.; Iwama, S.; Sugiyama, D.; Okuji, T.; Kobayashi, T.; Ito, M.; Okada, N.; Enomoto, A.; Ito, S.; Yan, Y.; Sugiyama, M.; Onoue, T.; Tsunekawa, T.; Ito, Y.; Takagi, H.; Hagiwara, D.; Goto, M.; Suga, H.; Banno, R.; Takahashi, M.; Nishikawa, H.; Arima, H. CD4 + T cells are essential for the development of destructive thyroiditis induced by anti–PD-1 antibody in thyroglobulin-immunized mice. Sci. Transl. Med., 2021, 13(593), eabb7495.
[http://dx.doi.org/10.1126/scitranslmed.abb7495] [PMID: 33980577]
[44]
Kotwal, A.; Gustafson, M.P.; Bornschlegl, S.; Kottschade, L.; Delivanis, D.A.; Dietz, A.B.; Gandhi, M.; Ryder, M. Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations. Thyroid, 2020, 30(10), 1440-1450.
[http://dx.doi.org/10.1089/thy.2020.0075] [PMID: 32323619]
[45]
Taylor, J.; Gandhi, A.; Gray, E.; Zaenker, P. Checkpoint inhibitor immune-related adverse events: A focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities. Front. Immunol., 2023, 13, 991433.
[http://dx.doi.org/10.3389/fimmu.2022.991433] [PMID: 36713389]
[46]
Vargas-Uricoechea, H. Molecular mechanisms in autoimmune thyroid disease. Cells, 2023, 12(6), 918.
[http://dx.doi.org/10.3390/cells12060918] [PMID: 36980259]
[47]
Inaba, H.; De Groot, L.J.; Akamizu, T. Thyrotropin receptor epitope and human leukocyte antigen in Graves’ disease. Front. Endocrinol., 2016, 7, 120.
[http://dx.doi.org/10.3389/fendo.2016.00120] [PMID: 27602020]
[48]
Muller, I.; Willis, M.; Healy, S.; Nasser, T.; Loveless, S.; Butterworth, S.; Zhang, L.; Draman, M.S.; Taylor, P.N.; Robertson, N.; Dayan, C.M.; Ludgate, M.E. Longitudinal characterization of autoantibodies to the thyrotropin receptor (TRAb) during alemtuzumab therapy: Evidence that TRAb may precede thyroid dysfunction by many years. Thyroid, 2018, 28(12), 1682-1693.
[http://dx.doi.org/10.1089/thy.2018.0232] [PMID: 30351224]
[49]
Dwivedi, S.N.; Kalaria, T.; Buch, H. Thyroid autoantibodies. J. Clin. Pathol., 2023, 76(1), 19-28.
[http://dx.doi.org/10.1136/jcp-2022-208290] [PMID: 36270794]
[50]
Hu, X.; Wang, L.; Shang, B.; Wang, J.; Sun, J.; Liang, B.; Su, L.; You, W.; Jiang, S. Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors. Front. Immunol., 2023, 14, 1094414.
[http://dx.doi.org/10.3389/fimmu.2023.1094414] [PMID: 36949956]

Rights & Permissions Print Cite
Article Metrics
Pdf icon 26
Html icon 2
Find your institution